Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
(2014) In World Journal of Diabetes 5(1). p.40-51- Abstract
- There are many advantages of combining incretin therapy [glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] with insulin therapy as a glucose-lowering strategy in type 2 diabetes. One important advantage is the complementary mode of the mechanistic action of incretin and insulin therapy. Another advantage is the reduction in risk of hypoglycemia and weight gain when adding incretin therapy to insulin. Several clinical trials have studied the addition of GLP-1 receptor agonists [exenatide BID (twice daily), lixisenatide, albiglutide] or DPP-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin) to ongoing insulin therapy or adding insulin to ongoing therapy with a GLP-1... (More)
- There are many advantages of combining incretin therapy [glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] with insulin therapy as a glucose-lowering strategy in type 2 diabetes. One important advantage is the complementary mode of the mechanistic action of incretin and insulin therapy. Another advantage is the reduction in risk of hypoglycemia and weight gain when adding incretin therapy to insulin. Several clinical trials have studied the addition of GLP-1 receptor agonists [exenatide BID (twice daily), lixisenatide, albiglutide] or DPP-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin) to ongoing insulin therapy or adding insulin to ongoing therapy with a GLP-1 receptor agonist (liraglutide). These studies show improved glycemia in the presence of limited risk for hypoglycemia and weight gain with the combination of incretin therapy with insulin. This article reviews the background and clinical studies on this combination. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4334016
- author
- Ahrén, Bo LU
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- World Journal of Diabetes
- volume
- 5
- issue
- 1
- pages
- 40 - 51
- publisher
- Baishideng Publishing Group
- external identifiers
-
- pmid:24567800
- pmid:24567800
- ISSN
- 1948-9358
- DOI
- 10.4239/wjd.v5.i1.40
- language
- English
- LU publication?
- yes
- id
- 2e74b5fa-199f-4a6e-a221-85166c61102e (old id 4334016)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24567800?dopt=Abstract
- date added to LUP
- 2016-04-04 09:24:18
- date last changed
- 2025-04-04 15:07:47
@article{2e74b5fa-199f-4a6e-a221-85166c61102e,
abstract = {{There are many advantages of combining incretin therapy [glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] with insulin therapy as a glucose-lowering strategy in type 2 diabetes. One important advantage is the complementary mode of the mechanistic action of incretin and insulin therapy. Another advantage is the reduction in risk of hypoglycemia and weight gain when adding incretin therapy to insulin. Several clinical trials have studied the addition of GLP-1 receptor agonists [exenatide BID (twice daily), lixisenatide, albiglutide] or DPP-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin) to ongoing insulin therapy or adding insulin to ongoing therapy with a GLP-1 receptor agonist (liraglutide). These studies show improved glycemia in the presence of limited risk for hypoglycemia and weight gain with the combination of incretin therapy with insulin. This article reviews the background and clinical studies on this combination.}},
author = {{Ahrén, Bo}},
issn = {{1948-9358}},
language = {{eng}},
number = {{1}},
pages = {{40--51}},
publisher = {{Baishideng Publishing Group}},
series = {{World Journal of Diabetes}},
title = {{Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.}},
url = {{http://dx.doi.org/10.4239/wjd.v5.i1.40}},
doi = {{10.4239/wjd.v5.i1.40}},
volume = {{5}},
year = {{2014}},
}